瑞戈非尼剂量优化策略在难治性转移性结直肠癌中的随机II期研究
ReDOS研究为随机、多中心、开放标签II期试验,纳入123例难治性转移性结直肠癌患者,比较瑞戈非尼剂量递增策略与标准剂量策略。剂量递增策略活性相当且不良事件发生率较低。
要点
- 剂量递增组启动第3周期比例43%,标准剂量组26%,差异有统计学意义。
- 剂量递增策略不良事件发生率较低,3-4级乏力、手足皮肤反应等发生率两组相近。
- 剂量递增策略可作为优化瑞戈非尼给药的替代方案。
核心结论
- 剂量递增策略在难治性转移性结直肠癌中表现出与标准剂量相当的活性,且不良事件发生率较低,可作为临床实践中的替代给药方案。
主要发现
- 14例患者发生至少一次药物相关严重不良事件:剂量递增组6例,标准剂量组8例;标准剂量组有1例可能治疗相关死亡(心肌梗死)。
关键数值与推荐
- 剂量递增策略:起始剂量80 mg/日口服,每周递增40 mg至160 mg/日,若无显著药物相关不良事件。
- 标准剂量策略:160 mg/日口服,28天周期中用药21天。
临床怎么用
- 对于难治性转移性结直肠癌患者,可考虑采用瑞戈非尼剂量递增策略以降低毒性并维持活性。
- 剂量递增策略需从80 mg/日开始,每周递增40 mg至160 mg/日,密切监测药物相关不良事件。
局限性
- 本研究为II期开放标签研究,样本量有限,需进一步验证。
- 主要终点为启动第3周期的比例,非总生存期等硬终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Regorafenib confers an overall survival benefit in patients with refractory metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its use. Despite no supportive evidence, various dosing schedules are used clinically to alleviate toxicities. This study evaluated the safety and activity of two regorafenib dosing schedules. METHODS: In this randomised, multicentre, open-label, phase 2 study done in 39 outpatient cancer centres in the USA, adults aged 18 years or older with histologically or cytologically confirmed advanced or metastatic adenocarcinoma of the colon or rectum that was refractory to previous standard therapy, including EGFR inhibitors if KRAS wild-type, were enrolled. Eligible patients had an Eastern Cooperative Oncology Group performance status of 0-1 and had no previous treatment with regorafenib. Patients were randomly assigned (1:1:1:1) into four groups with two distinct regorafenib dosing strategies and two clobetasol usage plans, stratified by hospital. Regorafenib dosing strategies were a dose-escalation strategy (starting dose 80 mg/day orally with weekly escalation, per 40 mg increment, to 160 mg/day regorafenib) if no significant drug-related adverse events occurred and a standard-dose strategy (160 mg/day orally) for 21 days of a 28-day cycle. Clobetasol usage plans (0·05% clobetasol cream twice daily applied to palms and soles) were either pre-emptive or reactive. After randomisation to the four preplanned groups, using the Pocock and Simon dynamic allocation procedures stratified by the treating hospitals, we formally tested the interaction between the two interventions, dosing strategy and clobetasol usage. Given the absence of a significant interaction (p=0·74), we decided to pool the data for the pre-emptive and reactive treatment with clobetasol and compared the two dosing strategies (dose escalation vs standard dose). The primary endpoint was the proportion of evaluable patients (defined as those who were eligible, consented, and received any protocol treatment) initiating cycle 3 and was analysed per protocol. Superiority for dose escalation was declared if the one-sided p value with Fisher's exact test was less than 0·2. This trial is registered with ClinicalTrials.gov, number NCT02368886. This study is fully accrued but remains active. FINDINGS: Between June 2, 2015, and June 22, 2017, 123 patients were randomly assigned to treatment, of whom 116 (94%) were evaluable. The per-protocol population consisted of 54 patients in the dose-escalation group and 62 in the standard-dose group. At data cutoff on July 24, 2018, median follow-up was 1·18 years (IQR 0·98-1·57). The primary endpoint was met: 23 (43%, 95% CI 29-56) of 54 patients in the dose-escalation group initiated cycle 3 versus 16 (26%, 15-37) of 62 patients in the standard-dose group (one-sided p=0·043). The most common grade 3-4 adverse events were fatigue (seven [13%] patients in the dose-escalation group vs 11 [18%] in the standard-dose group), hand-foot skin reaction (eight [15%] patients vs ten [16%] patients), abdominal pain (nine [17%] patients vs four [6%] patients), and hypertension (four [7%] patients vs nine [15%] patients). 14 patients had at least one drug-related serious adverse event: six patients in the dose-escalation group and eight patients in the standard-dose group. There was one probable treatment-related death in the standard-dose group (myocardial infarction). INTERPRETATION: The dose-escalation dosing strategy represents an alternative approach for optimising regorafenib dosing with comparable activity and lower incidence of adverse events and could be implemented in clinical practice on the basis of these data. FUNDING: Bayer HealthCare Pharmaceuticals.
引用
- Bekaii-Saab TS, Ou FS, Ahn DH, et al. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol. 2019. PMID: 31262657. doi:10.1016/S1470-2045(19)30272-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。